Nuron Biotech
Exton · Founded 2010
About Nuron Biotech
Nuron Biotech Inc. develops specialty biologics and vaccines. Its product pipeline comprises central nervous system products, such as NU100, a recombinant human interferon beta-1b for the treatment of relapsing remitting multiple sclerosis; wound healing products, including NU200, a recombinant human epidermal growth factor product for healing diabetic foot ulcers and burns; and HibTITER, a conjugate vaccine. The company was founded in 2010 and is based in Exton, Pennsylvania.
Company Facts
- Founded: 2010
- Legal name: Nuron Biotech, Inc.
- Operating status: Operating
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $10K – $50K
- Total funding: $102.7M
- Funding stage: Private Equity
- Last round: Private Equity (Feb 2014)
- Website: nuronbiotech.com
- Phone: +1 610-968-6700
Social Profiles
Canonical: https://fsome.com/organization/nuron-biotech-8283433 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.